2003
DOI: 10.1007/s00431-003-1343-3
|View full text |Cite
|
Sign up to set email alerts
|

Technology challenges in screening single gene disorders

Abstract: The completion of the human genome project and the accelerated discovery of genes responsible for single gene disorders will allow for the preventive screening of carriers and patients. Accuracy and reliability of analytic tests are major demands on technologies used in a diagnostic screening environment. The consistency of results and the potential of multiplexing suggest mass spectrometry as the method of choice for large-scale genetic screening programs. The added ability to analyze other large molecules su… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
9
0

Year Published

2005
2005
2016
2016

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 8 publications
0
9
0
Order By: Relevance
“…SNP genotyping in this sample was carried out with Mass-ARRAY system (Sequenom, San Diego, CA, USA) using matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (Braun et al 2003) for separation and detection. The entire process has been designed for complete automation including assay design, PCR setup, post-PCR treatment, nanoliter transfer of diagnostic products onto silicon chips, serial reading of chip positions in the mass spectrometer, and final analytical interpretation.…”
Section: Genotypingmentioning
confidence: 99%
“…SNP genotyping in this sample was carried out with Mass-ARRAY system (Sequenom, San Diego, CA, USA) using matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (Braun et al 2003) for separation and detection. The entire process has been designed for complete automation including assay design, PCR setup, post-PCR treatment, nanoliter transfer of diagnostic products onto silicon chips, serial reading of chip positions in the mass spectrometer, and final analytical interpretation.…”
Section: Genotypingmentioning
confidence: 99%
“…[18] Primers were designed using MassARRAY Assay Design 3.1 software. Genotyping quality control procedures leading to SNP exclusion were the following: call rate <90%, MAF <0.05 in the total sample and P <0.001 for deviations from HWE in controls.…”
Section: Methodsmentioning
confidence: 99%
“…Genotypes were obtained using MALDI-TOF mass spectrometry on a Sequenom system (Sequenom, Inc., San Diego, CA) with iPLEX assay [27]. Primers were designed using MassARRAY Assay Design 3.1 software.…”
Section: Methodsmentioning
confidence: 99%